An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT]

Trial Profile

An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT]

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ASCENT
  • Sponsors Roche
  • Most Recent Events

    • 20 Jan 2018 Primary endpoint (Neutrophil to Lymphocyte Ratio (NLR) for an Association With PFS) has not been met, according to results presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results assessing the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 01 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top